Endothelial progenitor cells are associated with improved vascular repair in experimental aortic dissection Authors: Pengcheng Du, Guanglang Zhu, Zhiqing Zhao, Yudong Sun, Zaiping Jing, Jiaxuan Feng Published: 2026 ABSTRACT Aortic dissection (AD) is a life-threatening vascular disorder for which current mechanical interventions provide limited biological repair of the injured aortic wall. Here, we evaluated the short-term reparative potential of systemic endothelial progenitor cell (EPC) therapy in AD. We observed increased accumulation of CD34 + VEGFR2+ EPC-like cells in human AD tissues, particularly in regions of intimal injury, although these findings should be interpreted as an injury-associated tissue response rather than definitive evidence of endogenous protection. In a murine model of AD, transplanted EPCs preferentially localized to the injured aorta and were associated with reduced aortic dilation, improved re-endothelialization, and preservation of extracellular matrix architecture within the aortic wall. These findings suggest that EPC administration may support vascular repair in experimental AD during the early phase after injury. However, the relative contributions of transplanted versus endogenous EPCs, the precise mechanisms involved, and the long-term durability of repair remain to be determined. Collectively, our results provide preliminary preclinical support for further investigation of EPC-based biological strategies in AD.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52893-x. Introduction Aortic dissection (AD) represents a critical vascular emergency characterized by a rupture in the intimal layer of the aorta. This rupture permits the ingress of blood into the media, thereby creating a false lumen and undermining the stability of the aortic wall1. The intima, particularly its endothelial layer, plays a pivotal role in maintaining the structural and functional integrity of the aortic wall. It serves as a protective barrier that regulates the vascular microenvironment and shields the media from direct hemodynamic stress. Disruption of this barrier can precipitate the development of AD, leading to progressive medial degeneration and potentially fatal complications2–4. Although AD is relatively uncommon, it is associated with high mortality, particularly in Stanford type A dissection, for which in-hospital mortality remains substantial despite surgical intervention5,6. Current surgical and endovascular strategies primarily aim to prevent rupture and restore aortic flow, but they provide limited biological repair of the injured vessel wall and may be complicated by endoleaks, retrograde dissection, or the need for reintervention7,8. These limitations underscore the need for therapeutic approaches that complement mechanical stabilization with vascular repair9. Endothelial progenitor cells (EPCs), initially described by Asahara and colleagues, are bone marrow-derived progenitors implicated in vascular regeneration. EPCs can migrate to sites of vascular injury, adopt endothelial-like properties, and contribute to restoration of vascular integrity under experimental conditions10,11. Their reparative potential has been demonstrated in several preclinical models of vascular injury, in which systemic EPC administration promoted re-endothelialization and neovascularization12. Clinically, reduced EPC number and impaired EPC function have been associated with adverse cardiovascular outcomes13. In addition, patients with AD have been reported to exhibit EPC dysfunction in association with systemic inflammation14, suggesting that endogenous EPC-mediated repair may be quantitatively or functionally limited in this setting. Recent advances in vascular biology have emphasized that aortic remodeling is shaped by complex interactions among endothelial injury, immune-cell-driven inflammation, smooth muscle cell plasticity, extracellular matrix remodeling, and resident vascular progenitor populations15,16. Within this framework, the role of circulating EPCs in AD remains incompletely understood. Because the dissecting aorta is characterized by inflammation, matrix degradation, and altered hemodynamic stress, it remains uncertain whether systemically administered EPCs can localize to injured tissue and support vascular repair in vivo. We therefore hypothesized that transplantation of functional, ex vivo-expanded EPCs may support early vascular repair in AD by enhancing re-endothelialization and preserving aortic wall structure. To test this hypothesis, we aimed to1 examine the distribution of EPC-like cells in human AD tissue2, evaluate EPC-associated vascular effects using ex vivo and in vitro assays, and3 assess the short-term impact of EPC administration in a murine model of AD. These experiments were designed to provide an initial preclinical framework for evaluating EPC-based regenerative strategies in aortic disease, while recognizing that the precise mechanisms of action remain to be defined. Results Accumulation of EPC-Like cells in human aortic dissection tissue To assess the clinical relevance of EPCs in aortic dissection, we analyzed the distribution of CD34 + VEGFR2+ EPC-like cells in aortic tissues obtained from seven patients with AD and seven healthy organ donors. Baseline clinical characteristics, including age, sex, and the absence of atherosclerosis, did not differ significantly between the two groups (Supplementary Table 1). Immunofluorescence staining for the EPC-associated markers CD34 and VEGFR2 revealed a significant increase in CD34 + VEGFR2+ cells within the aortic walls of AD patients compared with healthy controls (Figs. 1A-B, P < 0.05). To further localize these EPC-like cells within the aortic wall, we examined different tissue layers. CD34 + VEGFR2+ cells were most abundant in the intima, where their density was significantly increased (Figs. 1C-D, P < 0.05). A similar increase was observed at the intima-media border (Figs. 1E-F, P < 0.05). By contrast, no significant difference in CD34 + VEGFR2+ cell counts was detected within the aortic media between the AD and control groups (Figs. 1G-H, P > 0.05). These findings indicate that EPC-like cells accumulate preferentially in regions of intimal injury in human AD tissue; however, whether this represents an effective endogenous reparative response or a broader injury-associated vascular reaction remains unresolved. Fig. 1Enhanced Accumulation of EPC-Like Cells in Human Aortic Dissection Tissue. (A) Immunofluorescence images of aortic wall sections from control and aortic dissection (AD) patients stained for the EPC-associated markers CD34 (green) and VEGFR2 (red), with DAPI (blue) as a nuclear counterstain. (B) Quantification of CD34 + VEGFR2+ cells per high-power field (HPF) in aortic wall sections from control (n = 7) and AD (n = 7) patients. (C, E, G) High-magnification images showing localization of CD34 + VEGFR2+ cells in the intima (C), intima-media border (E), and aortic media (G). (D, F, H) Corresponding quantification of CD34 + VEGFR2+ cells in each aortic wall layer in the control and AD groups. Data are presented as mean ± SD; *P < 0.05. Enhanced Accumulation of EPC-Like Cells in Human Aortic Dissection Tissue. (A) Immunofluorescence images of aortic wall sections from control and aortic dissection (AD) patients stained for the EPC-associated markers CD34 (green) and VEGFR2 (red), with DAPI (blue) as a nuclear counterstain. (B) Quantification of CD34 + VEGFR2+ cells per high-power field (HPF) in aortic wall sections from control (n = 7) and AD (n = 7) patients. (C, E, G) High-magnification images showing localization of CD34 + VEGFR2+ cells in the intima (C), intima-media border (E), and aortic media (G). (D, F, H) Corresponding quantification of CD34 + VEGFR2+ cells in each aortic wall layer in the control and AD groups. Data are presented as mean ± SD; *P < 0.05. Phenotypic and functional characteristics of bone marrow-derived endothelial progenitor cells To establish a reliable cellular source for therapeutic studies, we isolated and expanded primary EPCs from the bone marrow of C57BL/6 mice. Following density-gradient centrifugation, freshly isolated mononuclear cells initially appeared as non-adherent round cells on day 0. By day 3, most cells had adhered to the fibronectin-coated surface, and by day 5, colonies exhibiting a characteristic radial growth pattern had developed (Fig. 2A). Cells at the center of the colonies were tightly packed, whereas peripheral cells adopted a spindle-shaped morphology and proliferated rapidly. Between days 7 and 9, most cells displayed polygonal or elongated spindle-like shapes resembling immature endothelial cells, although a small fraction retained a round morphology. By days 12 to 14, the cultures predominantly consisted of cells with a cobblestone-like monolayer appearance, indicative of endothelial lineage differentiation (Fig. 2A). To confirm their identity, we performed flow cytometry after approximately 14 days in culture. The majority of cells expressed progenitor- and endothelial-associated markers, including Sca-1 (95.8%) and Flk-1/VEGFR2 (91.9%) (Fig. 2B), supporting their classification as a functionally defined EPC population. Functional validation further demonstrated endothelial-like properties. The EPCs exhibited robust uptake of DiI-acetylated LDL (red cytoplasmic staining) and strong binding to FITC-conjugated Ulex europaeus agglutinin I (UEA-I) (green membrane staining). In combination with DAPI nuclear staining, double-positive cells appeared orange with blue nuclear counterstaining, confirming endothelial-associated functionality (Fig. 2C). Collectively, these findings indicate that the cultured cells exhibited phenotypic and functional features consistent with a functionally defined EPC population, although cellular heterogeneity cannot be fully excluded. Fig. 2Phenotypic and Functional Characterization of Mouse Bone Marrow-Derived Endothelial Progenitor Cells. (A) Brightfield images showing the morphological progression of cultured EPCs: suspended round mononuclear cells at day 0; colony formation with radial growth at day 5; spindle-like or polygonal morphology at days 7–9; and cobblestone-like monolayers at days 12–14. (B) Flow cytometric analysis of cultured EPCs at day 14 showing high expression of progenitor and endothelial markers, including Sca-1 (95.8%) and Flk-1/VEGFR2 (91.9%). (C) Functional validation of EPCs by uptake of DiI-Ac-LDL (red), binding of FITC-UEA-I (green), and DAPI nuclear staining (blue). Merged images show double-positive EPCs (orange cytoplasm, blue nuclei). Scale bar: 100 μm. Phenotypic and Functional Characterization of Mouse Bone Marrow-Derived Endothelial Progenitor Cells. (A) Brightfield images showing the morphological progression of cultured EPCs: suspended round mononuclear cells at day 0; colony formation with radial growth at day 5; spindle-like or polygonal morphology at days 7–9; and cobblestone-like monolayers at days 12–14. (B) Flow cytometric analysis of cultured EPCs at day 14 showing high expression of progenitor and endothelial markers, including Sca-1 (95.8%) and Flk-1/VEGFR2 (91.9%). (C) Functional validation of EPCs by uptake of DiI-Ac-LDL (red), binding of FITC-UEA-I (green), and DAPI nuclear staining (blue). Merged images show double-positive EPCs (orange cytoplasm, blue nuclei). Scale bar: 100 μm. Endothelial progenitor cells enhance angiogenic sprouting from aortic ring explants ex vivo To assess the pro-angiogenic activity of EPCs, we performed an ex vivo aortic ring assay. Murine thoracic aortic rings were embedded in Matrigel and co-cultured with either EPCs or control medium for 7 days (Fig. 3A). Aortic rings co-cultured with EPCs showed a significant increase in the number of microvascular sprouts (20.00 ± 2.92 versus 11.67 ± 6.08 in controls; P < 0.05), as well as increased average sprout length (87.86 ± 39.25 μm versus 62.53 ± 31.57 μm; P < 0.05) (Fig. 3B). Whole-mount immunofluorescence staining demonstrated that the sprouts contained both CD31 + endothelial cells and α-SMA+ smooth muscle marker-positive cells (Fig. 3C). Fig. 3Endothelial Progenitor Cells Enhance Angiogenic Sprouting from Aortic Ring Explants Ex Vivo. (A) Representative images of murine aortic rings cultured for 7 days in control medium or co-cultured with EPCs, showing increased sprouting in the EPC group. (B) Quantification of microvascular sprout number and average sprout length (n = 6 per group). Data are presented as mean ± SD; P < 0.05. (C) Whole-mount immunofluorescence staining of sprouts from the EPC group showing CD31 (green), α-smooth muscle actin (α-SMA, red), and nuclei (DAPI, blue), demonstrating the presence of CD31 + endothelial cells and α-SMA+ smooth muscle marker-positive cells. Scale bar: 100 μm. Endothelial Progenitor Cells Enhance Angiogenic Sprouting from Aortic Ring Explants Ex Vivo. (A) Representative images of murine aortic rings cultured for 7 days in control medium or co-cultured with EPCs, showing increased sprouting in the EPC group. (B) Quantification of microvascular sprout number and average sprout length (n = 6 per group). Data are presented as mean ± SD; P < 0.05. (C) Whole-mount immunofluorescence staining of sprouts from the EPC group showing CD31 (green), α-smooth muscle actin (α-SMA, red), and nuclei (DAPI, blue), demonstrating the presence of CD31 + endothelial cells and α-SMA+ smooth muscle marker-positive cells. Scale bar: 100 μm. Systemically administered endothelial progenitor cells preferentially localize to sites of aortic injury To investigate the localization of transplanted EPCs in the injured aorta, EPCs were labeled with the fluorescent dye CM-DiI prior to tail-vein injection. Fluorescence microscopy confirmed successful labeling, with distinct red fluorescence visible along the cell membrane (Fig. 4B). In the murine AD model, aortic injury was induced by BAPN administration followed by Ang II infusion, and EPCs were administered after completion of Ang II infusion, when aortic dilation had already been detected by high-frequency ultrasound, as an early post-injury treatment (Fig. 4A). Whole-body fluorescence imaging performed 3 days after EPC injection showed a prominent signal in the thoracic region (Fig. 4Ca). Subsequent dissection on day 4 confirmed that the fluorescence corresponded to the site of aortic injury (Fig. 4Cb). Further histological examination of frozen aortic sections identified DiI+ cells within the aortic wall, with partial overlap between the DiI signal and DAPI-stained nuclei, supporting localization of transplanted EPCs to the injured vascular tissue (Fig. 4D). Quantitative analysis demonstrated a significantly higher number of DiI+ cells in the EPC-transplanted group than in the Ang II + PBS and sham groups (Fig. 4E, P < 0.001). Collectively, these findings provide in vivo evidence that systemically delivered EPCs preferentially localize to regions of aortic injury. However, the extent of durable cellular incorporation and the relative contribution of transplanted versus endogenous reparative cell populations remain unresolved. Prior to EPC administration, successful induction of aortic injury was assessed by high-frequency ultrasound imaging. Compared with control mice, model mice exhibited marked aortic dilation and hyperechoic lesions adherent to the vessel wall in B-mode, consistent with mural thrombus or false lumen formation. Color Doppler imaging further revealed disturbed blood-flow signals in these regions, whereas control mice displayed uniform laminar flow (Supplementary Fig. 1). Fig. 4Systemically Administered Endothelial Progenitor Cells Preferentially Localize to Sites of Aortic Injury. (A) Schematic representation of the experimental timeline showing administration of β-aminopropionitrile (BAPN), Angiotensin II (Ang II), and EPC transplantation in C57BL/6 mice. EPCs were administered after completion of Ang II infusion, when aortic dilation had already been detected by high-frequency ultrasound, representing an early post-injury treatment design. (B) Representative fluorescence microscopy images of CM-DiI-labeled EPCs before transplantation, showing distinct red fluorescence along the cell membrane (×200 magnification). (C) In vivo and ex vivo imaging of DiI-labeled EPCs after tail-vein injection. (a) Whole-body fluorescence imaging performed 3 days after EPC transplantation, demonstrating a prominent signal in the thoracic region. (b) Gross dissection on day 4 showing fluorescence localized to the site of aortic injury. (D) Histological analysis of frozen aortic sections. Merged and enlarged images of DAPI (blue) and DiI (red) show the presence of DiI+ EPCs within the aortic wall, with partial overlap with cell nuclei (×5 and ×150 magnification). (E) Quantification of DiI+ cells in the aortic wall showed a significantly higher number in the EPC-transplanted group than in the Ang II + PBS and sham groups (P < 0.001). Systemically Administered Endothelial Progenitor Cells Preferentially Localize to Sites of Aortic Injury. (A) Schematic representation of the experimental timeline showing administration of β-aminopropionitrile (BAPN), Angiotensin II (Ang II), and EPC transplantation in C57BL/6 mice. EPCs were administered after completion of Ang II infusion, when aortic dilation had already been detected by high-frequency ultrasound, representing an early post-injury treatment design. (B) Representative fluorescence microscopy images of CM-DiI-labeled EPCs before transplantation, showing distinct red fluorescence along the cell membrane (×200 magnification). (C) In vivo and ex vivo imaging of DiI-labeled EPCs after tail-vein injection. (a) Whole-body fluorescence imaging performed 3 days after EPC transplantation, demonstrating a prominent signal in the thoracic region. (b) Gross dissection on day 4 showing fluorescence localized to the site of aortic injury. (D) Histological analysis of frozen aortic sections. Merged and enlarged images of DAPI (blue) and DiI (red) show the presence of DiI+ EPCs within the aortic wall, with partial overlap with cell nuclei (×5 and ×150 magnification). (E) Quantification of DiI+ cells in the aortic wall showed a significantly higher number in the EPC-transplanted group than in the Ang II + PBS and sham groups (P < 0.001). Transplantation of endothelial progenitor cells attenuates aortic dilation in a murine model of aortic dissection At the study endpoint, gross examination showed that aortas from EPC-treated mice exhibited less dilation than those from the Ang II + PBS group (Fig. 5A). Kaplan–Meier analysis demonstrated a numerical improvement in survival in the Ang II + EPC group compared with the Ang II + PBS group; however, this difference did not reach statistical significance within the current sample size and observation period (Fig. 5B). Similarly, the incidence of aortic rupture was lower in the Ang II + EPC group, but this difference was not statistically significant (Fig. 5C). High-frequency ultrasound further demonstrated reduced aortic expansion in EPC-treated mice (Fig. 5D). Quantitative assessment of the internal diameter at the primary lesion site (S4) at the study endpoint confirmed that EPC treatment significantly attenuated pathological aortic dilation (Fig. 5E, P < 0.05). Collectively, these findings suggest that EPC therapy was associated with attenuation of short-term aortic remodeling in murine AD, whereas effects on survival-related endpoints were not statistically demonstrated under the current experimental conditions. Fig. 5Transplantation of Endothelial Progenitor Cells Attenuates Aortic Dilation in a Murine Model of Aortic Dissection. (A) Representative gross images of aortic specimens collected 7 days after treatment from the PBS, Ang II + PBS, and Ang II + EPC groups. (B) Kaplan–Meier survival curves of the experimental groups during the observation period. The Ang II + EPC group showed a numerical improvement in survival compared with the Ang II + PBS group, but the difference was not statistically significant. (C) Incidence of aortic rupture among the experimental groups during the observation period. Rupture events were fewer in the Ang II + EPC group than in the Ang II + PBS group, but the difference was not statistically significant. (D) Representative high-frequency ultrasound images showing reduced aortic expansion in EPC-treated mice at indicated time points. (E) Comparative analysis of internal diameters at the primary lesion site at the study endpoint (7 days after EPC transplantation) between the Ang II + EPC and Ang II + PBS groups. *P < 0.05. Transplantation of Endothelial Progenitor Cells Attenuates Aortic Dilation in a Murine Model of Aortic Dissection. (A) Representative gross images of aortic specimens collected 7 days after treatment from the PBS, Ang II + PBS, and Ang II + EPC groups. (B) Kaplan–Meier survival curves of the experimental groups during the observation period. The Ang II + EPC group showed a numerical improvement in survival compared with the Ang II + PBS group, but the difference was not statistically significant. (C) Incidence of aortic rupture among the experimental groups during the observation period. Rupture events were fewer in the Ang II + EPC group than in the Ang II + PBS group, but the difference was not statistically significant. (D) Representative high-frequency ultrasound images showing reduced aortic expansion in EPC-treated mice at indicated time points. (E) Comparative analysis of internal diameters at the primary lesion site at the study endpoint (7 days after EPC transplantation) between the Ang II + EPC and Ang II + PBS groups. *P < 0.05. EPCs facilitate endothelial recovery and mitigate aortic remodeling following injury To investigate the effects of EPC transplantation on vascular repair, we first assessed re-endothelialization by Evans Blue perfusion. Aortas from the Ang II + EPC group exhibited significantly reduced blue staining, indicating less endothelial denudation than those from the Ang II + PBS group (Figure 6A). Quantitative analysis confirmed that EPC transplantation significantly enhanced re-endothelialization (83.18% ± 4.22% vs. 75.47% ± 4.70%; P < 0.05) (Figure 6B). Histological examination by hematoxylin and eosin staining revealed pronounced neointimal formation in the Ang II + EPC group, which was not observed in either the Ang II + PBS or PBS groups (Figure 6C). Morphometric analysis indicated a significantly larger neointimal area in EPC-treated vessels than in controls (P < 0.05) (Figure 6D). To further evaluate vascular remodeling, we conducted cross-sectional morphometry at four predetermined levels of the ascending and thoracic aorta (Figure 6E, S1-S4). Both the Ang II + EPC and Ang II + PBS groups exhibited varying degrees of luminal expansion relative to PBS controls. Notably, EPC treatment significantly reduced dilation at S2 (innominate artery level, 1.27 ± 0.08 mm vs. 1.40 ± 0.13 mm) and S4 (aortic arch-thoracic junction, 1.28 ± 0.13 mm vs. 1.43 ± 0.13 mm; P < 0.05) compared with the Ang II + PBS group, whereas differences at S1 and S3 were not statistically significant (Figure 6F). These findings suggest that EPC treatment attenuated pathological dilation at selected lesion-prone sites under the current experimental conditions. Fig. 6Enhancement of Re-endothelialization and Attenuation of Aortic Remodeling by EPCs Following Aortic Injury. (A) Representative images of Evans Blue-perfused aortas obtained 7 days after treatment. Blue staining indicates endothelial denudation, which was markedly reduced in the Ang II + EPC group relative to the Ang II + PBS group. (B) Quantification of the re-endothelialized area (% of lumen, n = 8 per group). The Ang II + EPC group showed a statistically significant increase in re-endothelialization compared with the Ang II + PBS group (*P < 0.05). (C) Representative hematoxylin and eosin-stained cross-sections from the PBS, Ang II + PBS, and Ang II + EPC groups. Arrows indicate neointimal formation, which was observed in the EPC-treated group. Scale bar = 100 μm. (D) Quantification of neointimal area (n = 8 per group). EPC treatment significantly increased neointimal area compared with the PBS and Ang II + PBS groups (*P < 0.05). (E) Schematic showing four predefined cross-sectional levels (S1-S4) of the ascending and thoracic aorta used for morphometric analysis. (F) Ultrasound measurements of luminal diameters at S1-S4. The Ang II + EPC group showed reduced vessel dilation compared with the Ang II + PBS group, with statistically significant differences at S2 and S4 (*P < 0.05). (G) Representative immunofluorescence images of aortic sections stained for CD31 (green) and DAPI (blue), showing improved endothelial coverage in the Ang II + EPC group. Scale bar = 100 μm. (H) Quantification of CD31 + endothelial cells showed a higher density in aortas from the Ang II + EPC group than in the Ang II + PBS group (*P < 0.05). Enhancement of Re-endothelialization and Attenuation of Aortic Remodeling by EPCs Following Aortic Injury. (A) Representative images of Evans Blue-perfused aortas obtained 7 days after treatment. Blue staining indicates endothelial denudation, which was markedly reduced in the Ang II + EPC group relative to the Ang II + PBS group. (B) Quantification of the re-endothelialized area (% of lumen, n = 8 per group). The Ang II + EPC group showed a statistically significant increase in re-endothelialization compared with the Ang II + PBS group (*P < 0.05). (C) Representative hematoxylin and eosin-stained cross-sections from the PBS, Ang II + PBS, and Ang II + EPC groups. Arrows indicate neointimal formation, which was observed in the EPC-treated group. Scale bar = 100 μm. (D) Quantification of neointimal area (n = 8 per group). EPC treatment significantly increased neointimal area compared with the PBS and Ang II + PBS groups (*P < 0.05). (E) Schematic showing four predefined cross-sectional levels (S1-S4) of the ascending and thoracic aorta used for morphometric analysis. (F) Ultrasound measurements of luminal diameters at S1-S4. The Ang II + EPC group showed reduced vessel dilation compared with the Ang II + PBS group, with statistically significant differences at S2 and S4 (*P < 0.05). (G) Representative immunofluorescence images of aortic sections stained for CD31 (green) and DAPI (blue), showing improved endothelial coverage in the Ang II + EPC group. Scale bar = 100 μm. (H) Quantification of CD31 + endothelial cells showed a higher density in aortas from the Ang II + EPC group than in the Ang II + PBS group (*P < 0.05). Immunofluorescence staining for CD31 further supported these findings, demonstrating greater endothelial coverage in EPC-treated aortas (Figures 6G-H). Quantitative analysis revealed a significantly higher density of CD31+ endothelial cells in the Ang II + EPC group than in the Ang II + PBS group (Figure 6H). Collectively, these results indicate that EPC transplantation was associated with enhanced re-endothelialization and short-term improvement in structural readouts of vascular injury. Additional experiments assessing extracellular matrix integrity are presented in Supplementary Figure 2. Masson’s trichrome staining showed that EPC treatment was associated with improved organization of collagen fibers, with the collagen volume fraction approaching that of the PBS group and exceeding that of the Ang II + PBS group. Concurrently, Elastica van Gieson staining demonstrated better preservation of elastic fiber architecture in the EPC-treated group than in the Ang II + PBS group, with no significant difference relative to the PBS group. These supplementary findings indicate that EPC treatment was associated with preservation of extracellular matrix architecture within the aortic wall, although the molecular basis of this effect was not investigated in the present study. Discussion This study provides preliminary preclinical evidence that systemic EPC administration is associated with early repair-related changes in a murine model of AD. In particular, transplanted EPCs preferentially localized to injured aortic tissue and were associated with improved re-endothelialization, reduced aortic dilation, and preservation of aortic wall architecture within a short observation window. These findings support the possibility that EPC-based therapy may enhance vascular repair in experimental AD. However, the present data should be interpreted cautiously, as the study was not designed to define the precise cellular or molecular mechanisms responsible for these effects. An important initial observation was the increased abundance of CD34 + VEGFR2+ cells in human AD tissue, particularly in the intimal region. We interpret this finding cautiously. Rather than demonstrating a definitively protective endogenous mechanism, this enrichment may reflect a broader injury-associated response characterized by endothelial disruption, angiogenic activation, and recruitment of reparative cell populations. This interpretation is consistent with previous reports showing that circulating EPC number and function are often impaired in cardiovascular disease states, including AD, which may limit endogenous vascular repair capacity in a hostile inflammatory milieu14,17–21. In this context, our human tissue data should be viewed as observational support for EPC involvement in the local vascular response to AD, rather than evidence that endogenous EPC recruitment is by itself sufficient or functionally protective. The mechanistic basis of EPC-associated repair in this model remains incompletely defined. Although EPC treatment was associated with improved endothelial coverage and preservation of extracellular matrix (ECM) architecture, the present study does not distinguish whether these effects arise from direct cellular incorporation, paracrine signaling, modulation of resident vascular cells, or a combination of these processes. Similarly, although the ex vivo aortic ring assay demonstrated enhanced sprouting in the presence of EPCs, it does not establish direct smooth muscle support or transdifferentiation in vivo. Therefore, the mechanistic implications of the current study should be considered hypothesis-generating rather than definitive. Future studies incorporating lineage tracing, molecular profiling, and pathway-focused analyses will be required to clarify how EPC therapy interacts with endothelial recovery, vascular remodeling, and inflammatory signaling in AD22–27. Our ECM-related findings should also be interpreted conservatively. Histological analyses showed preservation of collagen and elastin architecture in EPC-treated aortas, suggesting improved structural integrity of the vessel wall. However, the molecular basis of this effect was not examined in the present study. We did not directly assess matrix synthesis, matrix degradation, protease activity, or signaling pathways regulating vascular remodeling. Accordingly, although EPC treatment was associated with histological preservation of matrix architecture, whether this reflects reduced matrix destruction, enhanced matrix repair, altered vascular smooth muscle cell behavior, or secondary effects of improved endothelial recovery remains unresolved24,26,28. Another important consideration is the definition of EPCs themselves. The identity of EPCs remains debated in the field, and the Sca-1+/VEGFR2 + phenotype combined with endothelial functional assays, although commonly used in experimental studies, does not guarantee a homogeneous endothelial progenitor population11,23,29,30. It therefore remains possible that the cultured cells used here included heterogeneous progenitor subsets with partially overlapping vascular or stromal properties. For this reason, the cells used in the present study are most appropriately regarded as a functionally defined EPC population. Although heterogeneity cannot be excluded, these cells consistently displayed endothelial-associated functional behavior in vitro, preferential localization to injured vascular tissue in vivo, and reproducible repair-associated effects under our experimental conditions. From a broader conceptual perspective, recent advances in aortic biology have emphasized that disease progression is shaped not only by endothelial injury, but also by smooth muscle cell plasticity, immune-cell-driven remodeling, and resident vascular progenitor populations15,16,26,27. Our findings should therefore be interpreted within this more complex framework. Although EPC administration was associated with improved endothelial and structural readouts, the present study did not directly determine whether these effects involved altered inflammatory responses, modulation of smooth muscle phenotypic switching, or interactions with resident vascular progenitor populations. Addressing these questions will be important for defining the biological role of EPC therapy in aortic remodeling and for positioning EPC-based interventions within current concepts of aortic disease pathogenesis. Several additional limitations should be acknowledged. First, the human cohort was relatively small, which limits the strength of inference regarding EPC accumulation in AD tissue. Second, the in vivo study was restricted to a 7-day endpoint and therefore does not establish long-term durability of repair, false lumen stability, or sustained protection against chronic vascular remodeling. Third, EPC administration was performed after completion of Ang II infusion, such that the current model should be interpreted as an early post-injury treatment paradigm rather than a purely preventive design. Even so, this approach still does not fully recapitulate the clinical scenario in which treatment is typically initiated after diagnosis of established AD. Fourth, although transplanted EPCs could be tracked within the injured aortic wall, the present study was not designed to quantify the total EPC pool or determine the relative contribution of endogenous versus exogenous EPCs to the observed repair-associated changes. Finally, the EPC dose and dosing schedule were not optimized. These issues warrant systematic investigation in future studies, including delayed treatment paradigms, dose-escalation strategies, repeated cell delivery, and longer follow-up in chronic or genetically driven models of aortic disease7,8,27. Another important limitation is that, although EPC treatment reduced aortic dilation and improved repair-associated readouts, the numerical differences observed in survival and rupture incidence did not reach statistical significance within the current sample size and short follow-up period. Thus, the present study should be interpreted primarily as evidence of short-term structural benefit rather than definitive proof of improvement in major clinical outcomes. Future studies with larger cohorts, longer observation, and dose optimization will be required to determine whether EPC therapy can meaningfully affect survival-related endpoints. In conclusion, our study suggests that systemic EPC administration is associated with early improvement in endothelial repair and preservation of aortic wall architecture in experimental AD. These findings provide preliminary preclinical support for EPC-based biological strategies in aortic disease. However, the relative contribution of transplanted versus endogenous EPCs, the precise mechanisms involved, the optimal dosing regimen, and the long-term durability and safety of repair remain to be determined. Methods Study approval Human tissue studies were approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (2025 Lin Lun Shen No. 256). Written informed consent was obtained from all participants or their legal representatives. Animal experiments were approved by the Shanghai Chedun Experimental Animal Ethics Committee (Approval No. AD2024213) and were conducted in accordance with institutional guidelines. All methodologies complied with relevant regulations and standards, and the study was reported in accordance with the ARRIVE guidelines. All surgical procedures were performed under sodium pentobarbital anesthesia (80 mg/kg, intraperitoneally), and mice were euthanized by cervical dislocation under deep anesthesia (sodium pentobarbital, 100 mg/kg, intraperitoneally) at the end of the experiments, in accordance with institutional protocols. Human aortic tissue samples Aortic dissection tissues (n = 7; all male) were obtained from patients undergoing surgical repair, whereas control tissues (n = 7; 6 male and 1 female) were obtained from age-matched organ donors. Patients with established connective tissue disorders, aneurysms, or malignancies were excluded from the study. Samples were fixed in 4% paraformaldehyde and subsequently processed for histological and immunofluorescence analyses. Animal model of aortic dissection and epc transplantation Male C57BL/6 mice, aged 3 weeks and weighing 7–12 g, were randomly assigned to three groups: PBS, Ang II + PBS, and Ang II + EPCs (n = 12 per group). Aortic dissection was induced by administration of β-aminopropionitrile (BAPN; 1 g/kg/day) in drinking water for 4 weeks beginning on day 1, followed by Angiotensin II infusion (1 µg/kg/min) for 3 days using an osmotic mini-pump. Mini-pump implantation was performed under sodium pentobarbital anesthesia (80 mg/kg, intraperitoneally). This model has been established as a reliable method for inducing aortic dissection31,32. After completion of Ang II infusion, when aortic dilation had already been detected by high-frequency ultrasound, EPCs (2 × 106 syngeneic cells) were administered via tail-vein injection, whereas control mice received PBS. Mice were euthanized 7 days after EPC transplantation. Additional details regarding mini-pump implantation are provided in the Supplemental Methods. Isolation, culture, and characterization of mouse bone marrow-derived epcs Bone marrow mononuclear cells were isolated from 4–8-week-old donor C57BL/6 mice using density-gradient centrifugation and were subsequently plated on fibronectin-coated dishes in EGM-2 medium33. After 7–10 days, the adherent EPCs exhibited the characteristic spindle-shaped morphology and were further characterized. Flow cytometry was employed to evaluate the expression of stem cell antigen-1 (Sca-1) and Flk-1/VEGFR230. Functional validation encompassed the uptake of DiI-acetylated LDL and binding of FITC–UEA-I lectin. Detailed protocols are available in the Supplemental Methods. EPC labeling and in vivo tracking Cultured EPCs were labeled with CM-DiI prior to transplantation via tail vein injection. Whole-body and ex vivo fluorescence imaging were performed on days 3–4 post-injection (IVIS Spectrum, PerkinElmer). Aortic cryosections were analyzed for DiI+ cells using fluorescence microscopy. Aortic ring sprouting assay Thoracic aortic rings (1 mm) from C57BL/6 mice were embedded in Matrigel and cultured with or without EPCs (5 × 10⁴/well) in EGM-2 medium for 7 days34,35. Angiogenic sprouting was quantified by measuring both the number and length of sprouts utilizing ImageJ software. High-frequency ultrasound imaging Aortic diameters were evaluated using a Vevo high-frequency imaging system (40 MHz probe). Ultrasound was used to assess aortic dilation after BAPN/Ang II treatment and to measure aortic diameters at predefined anatomical sites at the study endpoint, 7 days after EPC transplantation36. Assessment of re-endothelialization Seven days after EPC injection, mice were intravenously administered Evans Blue dye37. The excised aortas were photographed, and the percentage of unstained (re-endothelialized) area was quantified using ImageJ software. Histological and immunofluorescence analysis Paraffin sections were stained with hematoxylin and eosin (H&E), Masson’s trichrome, and Elastica van Gieson (EVG). Immunofluorescence on paraffin-embedded human aortic samples was performed using anti-CD34 and anti-VEGFR2 antibodies with tyramide signal amplification38. Mouse aortic sections and sprouts were stained with anti-CD31 and anti–α-smooth muscle actin (α-SMA), with DAPI employed as a nuclear counterstain. Quantification was conducted on randomly selected high-power fields. Statistical analysis Data are presented as mean ± standard deviation (SD). Each “n” represents an independent biological replicate (individual human sample, animal, or independently performed ex vivo experiment), unless otherwise specified. Normality of data distribution was assessed before selection of statistical tests. For comparisons between two groups, an unpaired Student’s t-test was used for normally distributed data, whereas the Mann–Whitney U test was used for nonnormally distributed data. For comparisons among three or more groups, one-way ANOVA followed by an appropriate post hoc multiple-comparison test was used for normally distributed data, whereas the Kruskal–Wallis test followed by Dunn’s multiple-comparison test was used for nonnormally distributed data. Survival curves were analyzed using the log-rank test. Image analysis and quantification were performed using ImageJ (Fiji-win64 version; National Institutes of Health, USA; https://fiji.sc/). A formal a priori power calculation was not performed, which is acknowledged as a limitation of the study. Statistical analyses were performed using GraphPad Prism (version 8.0; GraphPad Software, San Diego, CA, USA; https://www.graphpad.com) and IBM SPSS Statistics (version 19.0; IBM Corp., Armonk, NY, USA; https://www.ibm.com/products/spss-statistics). A two-sided P value < 0.05 was considered statistically significant. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1